It was found that the three genes most mutated in WHO grade 2 gliomas at initial diagnosis were: IDH1 in 100% (23/23), TP53 in 83% (19/23), and ATRX in 78% (18/23) in the cohort studied. Here, ATRX is linked to central nervous system cancer.